These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 23727860)

  • 1. A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer.
    Lunardi A; Ala U; Epping MT; Salmena L; Clohessy JG; Webster KA; Wang G; Mazzucchelli R; Bianconi M; Stack EC; Lis R; Patnaik A; Cantley LC; Bubley G; Cordon-Cardo C; Gerald WL; Montironi R; Signoretti S; Loda M; Nardella C; Pandolfi PP
    Nat Genet; 2013 Jul; 45(7):747-55. PubMed ID: 23727860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-targeting hexokinase 2-mediated Warburg effect and ULK1-dependent autophagy suppresses tumor growth of PTEN- and TP53-deficiency-driven castration-resistant prostate cancer.
    Wang L; Wang J; Xiong H; Wu F; Lan T; Zhang Y; Guo X; Wang H; Saleem M; Jiang C; Lu J; Deng Y
    EBioMedicine; 2016 May; 7():50-61. PubMed ID: 27322458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opposing effects of androgen deprivation and targeted therapy on prostate cancer prevention.
    Jia S; Gao X; Lee SH; Maira SM; Wu X; Stack EC; Signoretti S; Loda M; Zhao JJ; Roberts TM
    Cancer Discov; 2013 Jan; 3(1):44-51. PubMed ID: 23258246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LINC00675 activates androgen receptor axis signaling pathway to promote castration-resistant prostate cancer progression.
    Yao M; Shi X; Li Y; Xiao Y; Butler W; Huang Y; Du L; Wu T; Bian X; Shi G; Ye D; Fu G; Wang J; Ren S
    Cell Death Dis; 2020 Aug; 11(8):638. PubMed ID: 32801300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sox2 is an androgen receptor-repressed gene that promotes castration-resistant prostate cancer.
    Kregel S; Kiriluk KJ; Rosen AM; Cai Y; Reyes EE; Otto KB; Tom W; Paner GP; Szmulewitz RZ; Vander Griend DJ
    PLoS One; 2013; 8(1):e53701. PubMed ID: 23326489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of dietary polyunsaturated fatty acids on castration-resistant Pten-null prostate cancer.
    Wang S; Wu J; Suburu J; Gu Z; Cai J; Axanova LS; Cramer SD; Thomas MJ; Perry DL; Edwards IJ; Mucci LA; Sinnott JA; Loda MF; Sui G; Berquin IM; Chen YQ
    Carcinogenesis; 2012 Feb; 33(2):404-12. PubMed ID: 22159221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
    Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP
    J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting prosurvival BCL2 signaling through Akt blockade sensitizes castration-resistant prostate cancer cells to enzalutamide.
    Pilling AB; Hwang C
    Prostate; 2019 Aug; 79(11):1347-1359. PubMed ID: 31228231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer.
    Guerrero J; Alfaro IE; Gómez F; Protter AA; Bernales S
    Prostate; 2013 Sep; 73(12):1291-305. PubMed ID: 23765603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced expression of the androgen receptor by third generation of antisense shows antitumor activity in models of prostate cancer.
    Zhang Y; Castaneda S; Dumble M; Wang M; Mileski M; Qu Z; Kim S; Shi V; Kraft P; Gao Y; Pak J; Sapra P; Bandaru R; Zhao H; Vessella RL; Horak ID; Greenberger LM
    Mol Cancer Ther; 2011 Dec; 10(12):2309-19. PubMed ID: 22027692
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Alzoubi A; Al Bashir S; Smairat A; Alrawashdeh A; Haddad H; Kheirallah K
    J Med Life; 2023 Apr; 16(4):593-598. PubMed ID: 37305830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic strategy for targeting therapy in castration-resistant prostate cancer.
    Mendiratta P; Mostaghel E; Guinney J; Tewari AK; Porrello A; Barry WT; Nelson PS; Febbo PG
    J Clin Oncol; 2009 Apr; 27(12):2022-9. PubMed ID: 19289629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Castration-resistant prostate cancer: a strategy to enhance response to androgen deprivation.
    Stanevsky Y; Tsivian A; Tsivian M
    Asian J Androl; 2013 Nov; 15(6):709-10. PubMed ID: 23893155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of androgen receptor antagonists with promising activity in castration-resistant prostate cancer.
    Shen HC; Balk SP
    Cancer Cell; 2009 Jun; 15(6):461-3. PubMed ID: 19477425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The steroid receptor coactivator-3 is required for the development of castration-resistant prostate cancer.
    Tien JC; Liu Z; Liao L; Wang F; Xu Y; Wu YL; Zhou N; Ittmann M; Xu J
    Cancer Res; 2013 Jul; 73(13):3997-4008. PubMed ID: 23650284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New agents and strategies for the hormonal treatment of castration-resistant prostate cancer.
    Sharifi N
    Expert Opin Investig Drugs; 2010 Jul; 19(7):837-46. PubMed ID: 20524793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities.
    Payne H; Bahl A; Mason M; Troup J; De Bono J
    BJU Int; 2012 Sep; 110(5):658-67. PubMed ID: 22429837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A rare castration-resistant progenitor cell population is highly enriched in Pten-null prostate tumours.
    Sackmann Sala L; Boutillon F; Menara G; De Goyon-Pélard A; Leprévost M; Codzamanian J; Lister N; Pencik J; Clark A; Cagnard N; Bole-Feysot C; Moriggl R; Risbridger GP; Taylor RA; Kenner L; Guidotti JE; Goffin V
    J Pathol; 2017 Sep; 243(1):51-64. PubMed ID: 28603917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen.
    Evans MJ; Smith-Jones PM; Wongvipat J; Navarro V; Kim S; Bander NH; Larson SM; Sawyers CL
    Proc Natl Acad Sci U S A; 2011 Jun; 108(23):9578-82. PubMed ID: 21606347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines.
    Li Y; Chan SC; Brand LJ; Hwang TH; Silverstein KA; Dehm SM
    Cancer Res; 2013 Jan; 73(2):483-9. PubMed ID: 23117885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.